Nuvo Pharmaceuticals acquired the U.S. rights to Resultz head lice treatment from Piedmont Pharmaceuticals.
GlaxoSmithKline won U.S. approval for a new and improved shingles vaccine, the second of three key products the drugmaker expects approval for in 2017.
Ignyta updated results from its STARTRK-2 clinical trial of entrectinib in non-small cell lung cancer (NSCLC), causing company stock to jump about five percent before settling down.
Takeda Pharmaceutical announced a collaboration to help transform novel Stanford University research into next-generation treatments for diseases.
Novel Oxyntomodulin Based Therapy Bolsters Janssen’s Metabolism Portfolio SEOUL, South Korea–(BUSINESS WIRE)–Hanmi Pharmaceuticals Co., Ltd. (Hanmi)(KRX: 128940), a Korea-based pharmaceutical company, today announced that it has entered into an exclusive license agreement with Janssen Pharmaceuticals, Inc. (Janssen), for the development and commercialization of oxyntomodulin-based therapies including Hanmi’s HM12525A (LAPSGLP/GCG), a novel biologic GLP-1/Glucagon dual […]
NEW YORK — Deciphera Pharmaceuticals and Akari Therapeutics both secured $75 million in funding, which will be used to advance the pipelines of both companies, the companies said in separate statements this morning. Akari said the $75 million it raised will be used to advance the company’s lead product Coversin, a C5 complement inhibitor, […]